LDL cholesterol targets: what level is right for you?

LDL cholesterol goals by risk level under the 2026 ACC/AHA guideline, the PREVENT risk calculator, how Europe and the UK differ, and how to reach your goal.

LDL cholesterol targets: what level is right for you?

8 min - BioSense Team - 2025-01-09

  • level:understanding
  • LDL
  • cholestérol
  • SCORE2
  • risque cardiovasculaire
  • ESC/EAS 2025

LDL cholesterol: which target for your risk level?

LDL-Cholesterol: Goals & Actions

Your LDL cholesterol goal, the so-called "bad cholesterol", depends on your cardiovascular risk: according to the 2026 ACC/AHA guideline, it ranges from below 100 mg/dL (2.6 mmol/L) at borderline or intermediate risk to below 55 mg/dL (1.4 mmol/L) at very high risk. There is therefore no single normal level that applies to everyone.

Your LDL cholesterol is 140 mg/dL (3.6 mmol/L): for a friend, the doctor said nothing; for you, they talk about lowering it. This is not a contradiction. Published in March 2026, the new US guideline replaced the 2018 cholesterol guideline, brought back numeric LDL goals and changed the way risk is calculated. This article details the goals for each risk level, how that level is determined and the ways to reach them.

Why the LDL target depends on cardiovascular risk

LDL cholesterol is a direct cause of atherosclerosis: LDL particles enter the artery wall and form plaques there. Two rules, confirmed by dozens of trials, guide the recommendations:

  • the lower the LDL, the lower the risk: each reduction of about 39 mg/dL (1.0 mmol/L) cuts heart attacks, strokes and other major cardiovascular events by just over 20%;
  • the higher the starting risk, the greater the absolute benefit: lowering LDL by the same amount prevents many more events in someone who has already had a heart attack than in a young, healthy person.

That is why the goal is set according to risk. To read your whole panel (total cholesterol, HDL, triglycerides), see our guide to the lipid panel. Here, we focus on the LDL goal.

LDL targets by risk level

These are the goals of the 2026 ACC/AHA guideline, with risk estimated by the PREVENT equations over 10 years.

| Situation | LDL goal | Non-HDL goal | |---|---|---| | Low risk, below 3% | lifestyle, no set number | lifestyle, no set number | | Borderline risk, 3% to under 5% | below 100 mg/dL (2.6 mmol/L) | below 130 mg/dL (3.4 mmol/L) | | Intermediate risk, 5% to under 10% | below 100 mg/dL (2.6 mmol/L) | below 130 mg/dL (3.4 mmol/L) | | High risk, 10% or more | below 70 mg/dL (1.8 mmol/L) | below 100 mg/dL (2.6 mmol/L) | | Known cardiovascular disease | below 70 mg/dL (1.8 mmol/L) | below 100 mg/dL (2.6 mmol/L) | | Known cardiovascular disease at very high risk | below 55 mg/dL (1.4 mmol/L) | below 85 mg/dL (2.2 mmol/L) |

Whether to treat at borderline risk is decided in a discussion with your doctor. The goal applies if treatment is started.

How other countries set LDL targets

Two doctors may mention different numbers, partly because guidelines differ:

  • US prevention panel: the USPSTF does not set an LDL goal. In 2022, it recommended a statin for adults aged 40 to 75 with at least one risk factor and a 10-year risk of 10% or more (grade B), and a selective offer from 7.5% to under 10% (grade C). It found the evidence insufficient for starting a statin at 76 or older.
  • Europe: the 2019 ESC/EAS guidelines, confirmed in 2025, set goals below 116 mg/dL (3.0 mmol/L) at low risk, below 100 mg/dL (2.6 mmol/L) at moderate risk, below 70 mg/dL (1.8 mmol/L) at high risk and below 55 mg/dL (1.4 mmol/L) at very high risk, the last two with a reduction of at least 50%.
  • UK: NICE aims for a reduction of more than 40% in non-HDL cholesterol in prevention, and an LDL of 77 mg/dL (2.0 mmol/L) or less after a cardiovascular event.

How your cardiovascular risk level is determined

Situations that set cardiovascular risk directly

Some situations do not rely on the risk calculator alone. In the 2026 ACC/AHA guideline:

  • known atherosclerotic cardiovascular disease (heart attack, ischemic stroke, arterial disease) calls for treatment, with goals depending on whether risk is very high;
  • an LDL of 190 mg/dL (4.9 mmol/L) or higher calls for treatment, and the usual risk calculators do not apply in heterozygous familial hypercholesterolemia;
  • diabetes, chronic kidney disease of stage 3 or higher, or HIV, from age 40, are situations in which lipid-lowering treatment is advised regardless of the calculated risk.

The PREVENT calculation

For people without known disease, the doctor estimates the 10-year risk with the PREVENT equations, for ages 30 to 79. They replace the older Pooled Cohort Equations and take into account age, sex, blood pressure, total and HDL cholesterol, diabetes, smoking, kidney function and any treatments. PREVENT estimates run about 40% to 50% lower than the old calculator, which is why the thresholds were also lowered. A percentage from one tool should not be read with the thresholds of another.

Age weighs heavily in these scores: a 45-year-old nonsmoker with an LDL of 150 mg/dL (3.9 mmol/L) will often be at low risk, while a 68-year-old with the same value and high blood pressure may move to a higher level. In adults under 60, the guideline also looks at 30-year risk.

Cardiovascular risk enhancers

The 2026 ACC/AHA guideline lists factors that can justify a more active approach than the percentage alone suggests:

  • raised lipoprotein(a), at or above 125 nmol/L (50 mg/dL). It is mostly genetic and should be measured at least once in adulthood;
  • high-sensitivity CRP above 2 mg/L on more than one occasion, a sign of low-grade inflammation. Our article on CRP and silent inflammation explains it;
  • persistent triglycerides above 150 mg/dL (1.7 mmol/L) fasting or 175 mg/dL (2.0 mmol/L) non-fasting;
  • a family history of early cardiovascular disease (parent or sibling, men before 55, women before 65), a chronic inflammatory disease, a history of preeclampsia, gestational diabetes, preterm delivery or early menopause.

Coronary artery calcium scoring can also refine the decision, for men over 40 and women over 45 at borderline or intermediate risk. For an overall view that also includes blood sugar, kidneys and blood pressure, read our article on integrated cardiovascular prevention.

What the 2026 ACC/AHA guideline changed

Beyond the new risk tool, the guideline includes several practical points:

  • Goals are back. The 2018 guideline relied mainly on treatment intensity and percentage reductions. The 2026 guideline again gives LDL and non-HDL numbers.
  • Treatment starts earlier. The guideline stresses lifelong exposure, with lifestyle counseling from youth and earlier treatment considered in young adults with an LDL of 160 mg/dL (4.1 mmol/L) or higher or a strong family history.
  • Lipoprotein(a) is measured at least once, in every adult.
  • ApoB is used selectively, to assess the risk that remains in certain people once LDL and non-HDL goals are met.

Dietary supplements do not replace these treatments. The 2025 ESC/EAS update recommends against supplements or vitamins to lower LDL or cardiovascular risk (class III). In the US, the National Center for Complementary and Integrative Health notes that red yeast rice can contain monacolin K, which is chemically identical to lovastatin, in amounts you cannot know from the label. Products with enhanced or added lovastatin cannot legally be sold as supplements, and the FDA does not approve supplements before they are marketed.

How to lower your LDL cholesterol

Lowering LDL through lifestyle

It applies at every risk level:

  • replace saturated fats (processed meats, butter, full-fat cheese, pastries, palm oil) with unsaturated fats (olive and canola oils, nuts, fatty fish). The Dietary Guidelines for Americans keep saturated fat at no more than 10% of daily calories;
  • increase soluble fiber: oats, barley, beans, lentils, fruit;
  • limit highly processed foods;
  • move at least 150 minutes a week and lose weight if needed;
  • stop smoking, which does not change LDL much but sharply worsens risk.

The effect of diet on LDL is usually modest and varies widely from person to person, because genetics plays a major role. If your LDL stays high despite real effort, it is not a personal failure.

LDL treatments, decided with the doctor

When the gap to the goal is large, lifestyle is not enough. As an order of magnitude, a high-intensity statin lowers LDL by about 50% or more and a moderate-intensity statin by 30% to 49%. Other treatments can be added if needed: ezetimibe, PCSK9 antibodies, inclisiran or bempedoic acid, the last particularly in case of statin intolerance. The choice of medicine and dose belongs to the doctor, who takes into account your history, your other treatments and any pregnancy plans.

Muscle aches are often blamed on statins, but they are not always caused by the drug: if you have symptoms, talk about it rather than stopping on your own, as alternatives exist.

When to recheck LDL

  • After starting or adjusting a treatment: the 2026 ACC/AHA guideline recommends a lipid panel at 4 to 12 weeks.
  • After a lifestyle change: a similar delay is a reasonable way to see its effect, as your doctor suggests.
  • On stable treatment: every 6 to 12 months.
  • Without treatment and at low risk: at least every 5 years from age 19.

Comparing your results over time says more than a single value: our guide to comparing two blood tests explains how. Also keep an eye on triglycerides, which affect how LDL is calculated: see high triglycerides.

Frequently asked questions

What is a good LDL cholesterol level?

There is no single normal level: the goal depends on the cardiovascular risk assessed by your doctor. Under the 2026 ACC/AHA guideline, it ranges from below 100 mg/dL (2.6 mmol/L) to below 55 mg/dL (1.4 mmol/L). MedlinePlus lists below 100 mg/dL (2.6 mmol/L) as a general value for adults.

Is the reference value printed on my lab report enough?

No. The lab shows a single indicative value, the same for everyone, which does not match your personal goal. Only the risk level assessed by your doctor can set it.

Why did my LDL go up after menopause?

The drop in estrogen often raises LDL around menopause, even without any change in diet. It is a good time to have your risk recalculated with your doctor.

My LDL is above 190: is it genetic?

It may be. An untreated LDL of 190 mg/dL (4.9 mmol/L) or higher should prompt a search for familial hypercholesterolemia, which affects about one person in 200 to 250 and justifies screening relatives too.

Is a very low LDL dangerous?

Large trials have not shown major harm linked to very low LDL achieved with treatment. Monitoring the treatment nevertheless remains the doctor's responsibility.

*This article is for information only and does not replace medical advice. Only your doctor can assess your cardiovascular risk, set your LDL goal and decide on treatment.*

Import your blood test and get an educational reading of each of your biomarkers, placed in the context of your personal situation. Your data is hosted on servers located in France.

[→ Import my blood test](/en/onboarding/upload)

Sources and methodology

United States

United Kingdom

Europe

  • Mach F, Koskinas KC, Roeters van Lennep JE, et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. European Heart Journal 2025;46(42):4359-4378. DOI 10.1093/eurheartj/ehaf190.
  • European Society of Cardiology. What is new in the 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias, 2025.
  • Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias. European Heart Journal 2020;41(1):111-188. DOI 10.1093/eurheartj/ehz455.

*BioSense methodology: our content is based on guidance from US authorities and medical societies (such as the USPSTF, CDC, NIH, FDA, ACC/AHA and ADA), UK bodies (NICE, NHS), European societies and the WHO. Sources are listed by country, and differences between countries are stated when they matter.*